Related Experiment Video
Updated: Feb 23, 2026
11:10
Hyperinsulinemic-euglycemic Clamps in Conscious, Unrestrained Mice
Published on: November 16, 2011
95.9K
Glucagon-Like Peptide 1 Receptor Agonists for Type 2 Diabetes
1Memorial Hospital Diabetes Center, University of Colorado Health, Colorado Springs, CO.
Summary
Glucagon-like peptide 1 (GLP-1) receptor agonists effectively treat type 2 diabetes by lowering A1C and body weight. These medications offer a low risk of hypoglycemia, with gastrointestinal issues being the most common side effect.
Area of Science:
- Endocrinology
- Metabolic Diseases
- Pharmacology
Background:
- The incretin system plays a crucial role in glucose homeostasis.
- Incretin system function is often impaired in type 2 diabetes.
- Glucagon-like peptide 1 (GLP-1) is a key incretin hormone with glucose-lowering properties.
Purpose of the Study:
- To review the role of GLP-1 receptor agonists in managing type 2 diabetes.
- To discuss the efficacy, safety, and administration of available GLP-1 receptor agonists.
Main Methods:
- Review of currently approved GLP-1 receptor agonists in the United States.
- Analysis of clinical trial data regarding efficacy (A1C, body weight, blood pressure, lipids) and safety (hypoglycemia, gastrointestinal effects).
Main Results:
- GLP-1 receptor agonists demonstrated significant reductions in A1C (0.8-1.6%) and body weight (1-3 kg).
- These agents also showed benefits in lowering blood pressure and lipids.
- The primary adverse effects were gastrointestinal, with a low risk of hypoglycemia.
Conclusions:
- GLP-1 receptor agonists are valuable therapeutic options for type 2 diabetes management.
- Effective patient selection and education are essential for optimizing treatment outcomes.
- The use of GLP-1 receptor agonists represents a significant advancement in diabetes care.
Related Concept Videos
01:24Glucagon-like Receptor Agonists
1.1K
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
1.1K
01:06Oral Hypoglycemic Agents: Glinides
747
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
747
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
721
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
721
01:23Dipeptidyl Peptidase 4 Inhibitors
770
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
770
01:19Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
650
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
650
01:15Hypoglycemia and Glucagon
1.1K
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
1.1K